MRK · News · 20261113N
Regulatory Approval Milestones
Merck & Co., Inc. · 2026-11-13 · Importance 34 · Surprise 42 · In source text
The European Medicines Agency’s CHMP recommended expanding ENFLONSIA (clesrovimab) to prevent RSV lower respiratory tract disease in children up to 24 months old who remain at increased risk of severe disease through their second RSV season. The recommendation will be reviewed by the European Commission for authorization in the EU, Iceland, Liechtenstein and Norway, with a final decision expected within two months. ENFLONSIA is already approved in numerous countries for infants during their first RSV season.
Key facts
- The positive CHMP opinion for Merck's WELIREG plus lenvatinib was based on positive progression-free survival results from the Phase 3 LITESPARK-011 trial. source
- The EMA's CHMP recommended expanding Merck's ENFLONSIA indication to prevent RSV lower respiratory tract disease in children up to 24 months of age at increased risk for severe RSV disease through their second RSV season. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | The positive CHMP opinion for Merck's WELIREG plus lenvatinib was based on positive progression-free survival results from the Phase 3… |
| revenue | positive | probable | — | The EMA's CHMP recommended expanding Merck's ENFLONSIA indication to prevent RSV lower respiratory tract disease in children up to 24… |